drugset / Trial / NCT05773105
A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCC
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of cadonilimab combined with regorafenib in patients with HCC who progressed on systemic therapy.
Timeline
- Start
- 2023-09-19
- Primary completion
- 2026-03-30
- Completion
- 2026-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Regorafenib | Small molecule | 80 mg | Oral |